💡 Francesco Destro emphasizes it reduces costly physical experiments. The model forecasts issues like genetic instability for higher efficiency, aiming to enhance gene therapy manufacturing.
🔍 Two projects focus on batch and continuous processing. Future developments target broader applications. 🧬
Introduction:
The article discusses a groundbreaking development by researchers at MIT, who have created a digital twin—a bioreactor simulator designed to predict yields of adeno-associated viruses (AAV) in the production process using insect cells and baculovirus. This innovation aims to enhance the efficiency and cost-effectiveness of gene therapies, which often face challenges due to high manufacturing costs.
- Francesco Destro, PhD, led the development of a digital twin that models intracellular processes during AAV production, targeting reduced costs in gene therapies.
- The simulator allows manufacturers to input specific parameters related to baculovirus constructs and predict AAV yields and the occurrence of empty capsids, which can impede therapeutic effectiveness.
- The team has published initial findings on batch processing AAV production using this digital twin in the journal *Molecular Therapy Methods*.
- Continuous processing offers advantages over traditional mammalian cell methods, but it poses challenges such as genetic instability in baculovirus, potentially leading to high rates of defective viruses that halt production.
- Future plans include expanding the digital twin’s capabilities to model various processing scales and applications, drawing inspiration from its success in other industries to drive down costs in bioprocessing.
Conclusion:
The development of this digital twin represents a significant advancement in AAV production methodology, promising to alleviate some economic burdens associated with gene therapy manufacturing. By leveraging computational models to enhance bioprocess optimization, this technology could transform manufacturing standards and reduce developmental costs in the field, potentially leading to broader accessibility of gene therapies.
